Federal grants to Virtici LLC
Virtici LLC in Seattle, Washington received $12.0 million in federal grants from fiscal 2021 to 2025, across 12 awards. Its largest program was Allergy and Infectious Diseases Research, with $4.1 million. In fiscal 2025 it was awarded $1.9 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$12.0 million
- Awards12
- Awarded in FY 2025$1.9 million
- Largest award$3.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 4 | $2.0 million |
| FY 2022 | 5 | $2.4 million |
| FY 2023 | 5 | $2.6 million |
| FY 2024 | 5 | $3.0 million |
| FY 2025 | 3 | $1.9 million |
Programs that fund Virtici LLC
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 4 | $4.1 million |
| Cardiovascular Diseases Research | 1 | $2.7 million |
| Oral Diseases and Disorders Research | 3 | $2.5 million |
| Aging Research | 3 | $2.0 million |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 1 | $638,854 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 12 | $12.0 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| A novel IL-35 expressing probiotic platform for inducing allergen specific tolerance | Allergy and Infectious Diseases Research | July 14, 2021 | $3.0 million |
| A novel bispecific antibody for the treatment of idiopathic pulmonary fibrosis - project summary our objective is to produce a bispecific antibody, VTC-890, capable of binding two proinflammatory cytokines, light (TNFSF14) and TL1A (TNFSF15), for the treatment of idiopathic pulmonary fibrosis (IPF). | Cardiovascular Diseases Research | March 20, 2022 | $2.7 million |
| A novel peptide for the oral treatment and prevention of p. Gingivalis infection - project summary our goal is to develop a first-in-class oral peptide inhibitor for the treatment and prevention of gingivitis and periodontitis. Oral infection by p. Gingivalis leads to inflammation and bleeding of th | Oral Diseases and Disorders Research | September 19, 2024 | $1.6 million |
| A novel antibody that promotes neuronal integrity and neurogenesis for treating alzheimer's disease - project summary our goal is to develop a novel neuron-penetrating bispecific antibody that promotes neuronal integrity and neurogenesis for the treatment of ad. In the us alone, over 6 million ameri | Aging Research | September 19, 2022 | $1.2 million |
| A novel multiparameter blood test for early detection of alzheimer's disease - project summary our objective is to develop a blood-based diagnostic for pre-symptomatic detection of alzheimer's disease (AD) based on a multiparameter profiling (PREAMP). Currently there are over 18 million cases of ad | Aging Research | September 21, 2021 | $759,062 |
| A novel blood test for early diagnosis of frontotemporal lobar degeneration - project summary our objective is to develop a blood-based diagnostic for early diagnosis and classification of frontotemporal lobar degeneration (FTD). Ftd is a common presenile dementia that afflicts an estimated 60,000 p | Extramural Research Programs in the Neurosciences and Neurological Disorders | August 15, 2024 | $638,854 |
| A novel sublingual vaccine to prevent neisseria gonorrhoeae infection - project summary our goal is to advance a novel, safe and effective sublingual (SL) vaccine against neisseria gonorrhoeae (NG) infection. Antibiotic resistant ng is an interconnected global threat to people, animals, and the envi | Allergy and Infectious Diseases Research | April 19, 2023 | $613,000 |
| A novel small molecule for the treatment of periodontitis - project summary our goal is to develop a first-in-class inhibitor of p. Gingivalis colonization of oral biofilms as a treatment for periodontitis. Severe periodontitis affects more than 11% of the world's population, resulting in billions o | Oral Diseases and Disorders Research | August 29, 2022 | $602,819 |
| A novel anti-infective therapy for treating periodontitis - project summary our goal is to develop a first-in-class inhibitor of p. Gingivalis, t. Forsythia and t. Denticola for the treatment and prevention of periodontitis. These “red complex” bacteria are considered the causative species in period | Oral Diseases and Disorders Research | August 8, 2025 | $309,038 |
| A novel light/TL1A bispecific antibody for the treatment of fibrotic diseases - project summary our objective is to produce a bispecific antibody, VTC-890, capable of binding two proinflammatory cytokines, light (TNFSF14) and TL1A (TNFSF15), for the treatment of systemic sclerosis (SSC). Ssc is a ch | Allergy and Infectious Diseases Research | January 21, 2021 | $299,015 |
Questions people ask
How much federal grant money does Virtici LLC get?
$12.0 million in 12 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Virtici LLC the most?
The Department of Health and Human Services, with $12.0 million in 12 awards.
What is Virtici LLC's largest federal grant?
$3.0 million under Allergy and Infectious Diseases Research, with its first action in the period on July 14, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Virtici LLC?
Its largest are Allergy and Infectious Diseases Research, Cardiovascular Diseases Research and Oral Diseases and Disorders Research.
Other grant recipients in Seattle
- University of Washington
- Central Puget Sound Regional Transit Authority
- Fred Hutchinson Cancer Center
- King County Metro Transit
- Port of Seattle
- Seattle Children's Hospital
- Allen Institute
- Seattle Housing Authority
Largest federal grant recipients in Washington · Federal grants in Washington